Pacific Biosciences v. Personal Genomics Taiwan — Federal Circuit Upholds Optical Bioassay Patent
In a 714-day appellate proceeding before the Court of Appeals for the Federal Circuit, Pacific Biosciences and Personal Genomics Taiwan successfully defended the validity of US7767441B2, a patent covering optical detection-based bioassay systems for biomolecule identification. The Federal Circuit affirmed the patent’s patentability, delivering a clear win for the patent holders.
Federal Circuit affirms bioassay optical detection patent after validity challenge
Pacific Biosciences, Inc. and Personal Genomics Taiwan, Inc. jointly prosecuted an appeal before the United States Court of Appeals for the Federal Circuit, Case No. 22-1410, filed on 25 January 2022. The dispute centred on the patentability of US7767441B2, which covers a bioassay system incorporating optical detection apparatuses and methods for detecting biomolecules — technology central to next-generation sequencing and genomic analysis platforms.
The Federal Circuit issued its ruling on 9 January 2024, affirming the lower-level determination and upholding the patent’s validity. The basis of termination is recorded as ‘Patent Upheld,’ reflecting a successful defence against an invalidity or cancellation action. For Pacific Biosciences and Personal Genomics Taiwan, the affirmance consolidates their IP position in optical bioassay detection and forecloses the challenger’s avenue of attack through this proceeding.
The 714-day duration is consistent with typical Federal Circuit appeal timelines for complex patentability matters. The public record does not disclose the identity of the petitioner or challenger who initiated the invalidity or cancellation action below, nor the specific grounds argued. It remains unknown whether parallel proceedings or licensing implications were at play, but the affirmance is a commercially significant outcome in the competitive genomics instrumentation space.
Filing to settlement in 714 days
714 days — from filing to Federal Circuit decision on patentability challenge
Federal Circuit affirms: US7767441B2 patentability confirmed
What ‘AFFIRMED’ means in a Federal Circuit patentability appeal
An ‘AFFIRMED’ order from the Federal Circuit means the appellate court found no reversible error in the lower tribunal’s ruling upholding the patent. The challenged claims survive the invalidity or cancellation action as filed. This is the highest available appellate affirmation short of Supreme Court review, and it substantially reinforces the enforceability of US7767441B2.
Patentability confirmedUS7767441B2 claims survive invalidity challenge intact
When a patent is upheld on appeal following an invalidity or cancellation action, the confirmed claims carry greater legal weight in subsequent enforcement proceedings. Challengers who lost before the Federal Circuit face issue preclusion obstacles if they attempt to relitigate the same invalidity grounds. For Pacific Biosciences, this strengthens the patent’s defensive and licensing value in the optical genomics detection market.
Reinforced enforceabilityOptical bioassay IP landscape consolidates around Pacific Biosciences
The Federal Circuit’s affirmance signals that the optical detection bioassay claims in US7767441B2 are sufficiently robust to withstand a formal patentability challenge. Competitors and licensees operating in next-generation sequencing, single-molecule detection, or optical biosensor markets should treat this patent as a durable IP barrier. Freedom-to-operate analyses in this space should account for the now-affirmed claim scope.
Durable IP barrierAppeal arose from an invalidity or cancellation action below
The verdict cause is classified as an invalidity/cancellation action, suggesting the challenge likely originated in an inter partes review, post-grant review, or similar USPTO proceeding before reaching the Federal Circuit. The absence of a named defendant in the appellate record is consistent with petitioner-driven administrative proceedings where the challenger’s role differs from a district court defendant. The full challenger identity is not disclosed in the available public record.
Administrative origin likelyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pacific Biosciences, Inc. | Company | Genomics technology company — holder of US7767441B2 covering optical bioassay detectionSearch in Eureka ↗ |
| Defendant | Defendant | Company | No defendant identified in the public case record for this appellate proceedingSearch in Eureka ↗ |
| Plaintiff counsel | Derek C. Walter | Attorney | Counsel for Pacific Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Edward R. Reines | Attorney | Counsel for Pacific Biosciences, Inc.Search in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | Court of Appeals for the Federal Circuit — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The Federal Circuit’s order — ‘AFFIRMED’ on patentability — is terse but legally decisive. It confirms that every challenged claim of US7767441B2 survives the invalidity or cancellation action without modification. For the patent holders, the order closes the appellate avenue for this challenge and substantially raises the cost and complexity of any future attack on the same grounds. The challenger receives no relief and must either accept the outcome or seek the unlikely step of Supreme Court certiorari.
US7767441B2 — Optical bioassay system for biomolecule detection
US7767441B2 protects a bioassay system incorporating optical detection apparatuses and methods for detecting biomolecules. The patent, filed under application number US12/255044, covers the integration of optical sensing technology into bioassay platforms — a foundational capability in single-molecule sequencing, genomic analysis, and clinical diagnostics. The technical domain spans photonics-based detection, nanoscale confinement of fluorescent signals, and real-time sequencing chemistry, making this a broad and strategically valuable asset in the life sciences instrumentation space.
US7767441B2 sits at the intersection of optical engineering and genomic sequencing — a space dominated by Pacific Biosciences’ SMRT (Single Molecule, Real-Time) technology platform. The patent’s survival through a full invalidity or cancellation challenge and Federal Circuit appeal suggests the claims are well-constructed and difficult to design around. Competitors developing optical biosensors, nanopore-adjacent detection systems, or fluorescence-based sequencing instruments face a reinforced IP barrier. The co-involvement of Personal Genomics Taiwan also suggests international commercial reach for this patent family.
Should your team run an FTO against US7767441B2?
Any R&D or product team working on optical detection systems for genomic or biomolecular assays should treat US7767441B2 as a priority freedom-to-operate target. The Federal Circuit’s affirmance means the claims have been stress-tested at the highest appellate level. Companies developing fluorescence-based sequencing instruments, optical biosensor arrays, or single-molecule detection platforms — particularly those entering or expanding in the US or Taiwan markets — face meaningful infringement exposure if their products read on the affirmed claims.
PatSnap Eureka’s FTO Search Agent can map your product’s feature set against the claim language of US7767441B2, identify design-around opportunities, and flag continuation or related patents in the Pacific Biosciences portfolio that may pose additional risk. Setting up claim monitoring alerts for this patent and its family members ensures your team is notified of any new divisional filings or reissue activity that could extend the IP perimeter around optical bioassay detection.
Run a freedom-to-operate analysis on US7767441B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals on optical genomics and bioassay patent validity
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the genomics optical detection IP landscape
A Federal Circuit affirmance on patentability is rare and consequential. Here is what it means for competitors, licensees, and IP teams.
Affirmed patents carry elevated litigation risk for competitors
A patent upheld at the Federal Circuit level is materially harder to challenge again on the same grounds. Any company operating optical detection bioassay systems should treat US7767441B2 as a high-priority FTO target. The affirmance signals that Pacific Biosciences is willing to defend this asset through the full appellate process.
Personal Genomics Taiwan’s co-plaintiff role warrants monitoring
The joint prosecution of this appeal by both Pacific Biosciences and Personal Genomics Taiwan suggests a licensing or co-ownership structure around US7767441B2. IP teams tracking enforcement in the Asia-Pacific genomics space should map the relationship between these two entities, as it may indicate territorial licensing arrangements or co-development agreements.
Pacific v Defendant — key questions answered
The Federal Circuit affirmed the patentability of US7767441B2 on 9 January 2024, upholding the patent against an invalidity or cancellation challenge. The basis of termination is recorded as ‘Patent Upheld,’ meaning the challenged claims survived intact and are fully enforceable.
US7767441B2 covers a bioassay system incorporating optical detection apparatuses and methods for detecting biomolecules. It is central to Pacific Biosciences’ optical sequencing platform technology. The patent’s affirmance at the Federal Circuit reinforces its value as an IP barrier in the single-molecule sequencing and optical biosensor markets.
The absence of a named defendant is consistent with an appeal originating from an administrative invalidity or cancellation proceeding, such as an inter partes review (IPR) or post-grant review (PGR) before the USPTO’s Patent Trial and Appeal Board. In such proceedings, the challenger is typically a petitioner rather than a defendant, and the patent owner appeals a PTAB decision. The specific petitioner identity is not disclosed in the available public record.
A Federal Circuit affirmance is the highest available appellate ruling below the Supreme Court. It confirms that the lower tribunal correctly upheld the patent’s validity. The affirmed claims are substantially harder to challenge again on the same grounds due to issue preclusion principles, and the ruling strengthens the patent’s enforceability in licensing and infringement proceedings.
Personal Genomics Taiwan, Inc. is listed as a co-plaintiff/appellant alongside Pacific Biosciences, suggesting a shared legal interest in US7767441B2 — consistent with co-ownership, exclusive licensing, or a joint enforcement arrangement. The exact nature of their relationship is not detailed in the public appellate record, but their joint prosecution of the appeal signals a coordinated IP defence strategy.
PatSnap Eureka searches patents and litigation data to answer instantly.